Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for disorders of the immune system such as rheumatoid arthritis, multiple sclerosis. Rabeximod is a Phase 2 therapeutic candidate with a unique mode of action in rheumatoid arthritis. T20K is a Phase 1 therapeutic candidate for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com.